Literature DB >> 9524080

Detection of p21WAF1/Cip1 in brain metastases.

S Ruan1, G Fuller, V Levin, J M Bruner, W Zhang.   

Abstract

The p21WAF1/Cip1 (p21) protein, a negative regulator of G1 checkpoint control, was overexpressed in the majority of human gliomas. To investigate whether p21 expression in brain metastases from various systemic origins is similar to that in gliomas and whether p21 expression is regulated differently in brain metastases and in corresponding primary tumors, we used immunohistochemical staining to examine the expression of p21 in paraffin-embedded sections prepared from primary colon and breast carcinomas and from metastatic brain tumors that originated from colon, breast, lung, and kidney cancers and from melanoma. Our results showed that 56% (28 of 50) of the brain metastases samples have more than 1% p21-positive staining cells compared with 87% of primary gliomas reported previously. Among the samples analyzed, p21 expression in brain metastases from breast carcinomas was much higher than in primary breast carcinomas. In contrast, p21 expression in brain metastases from colon carcinomas was less than primary colon carcinomas. The results from this pilot study suggest that p21 expression is regulated differently in metastatic and primary tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9524080     DOI: 10.1023/a:1005972808311

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  24 in total

1.  The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells.

Authors:  W Poluha; D K Poluha; B Chang; N E Crosbie; C M Schonhoff; D L Kilpatrick; A H Ross
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

2.  Repair Defect in p21 WAF1/CIP1 -/- human cancer cells.

Authors:  E R McDonald; G S Wu; T Waldman; W S El-Deiry
Journal:  Cancer Res       Date:  1996-05-15       Impact factor: 12.701

3.  Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents.

Authors:  B St Croix; V A Flørenes; J W Rak; M Flanagan; N Bhattacharya; J M Slingerland; R S Kerbel
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

4.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

5.  Central nervous system metastasis from breast carcinoma. Autopsy study.

Authors:  Y Tsukada; A Fouad; J W Pickren; W W Lane
Journal:  Cancer       Date:  1983-12-15       Impact factor: 6.860

6.  Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation.

Authors:  J Wang; K Walsh
Journal:  Science       Date:  1996-07-19       Impact factor: 47.728

7.  Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1.

Authors:  Y Luo; J Hurwitz; J Massagué
Journal:  Nature       Date:  1995-05-11       Impact factor: 49.962

8.  Site-specific metastasis of mouse melanomas and a fibrosarcoma in the brain or meninges of syngeneic animals.

Authors:  G Schackert; I J Fidler
Journal:  Cancer Res       Date:  1988-06-15       Impact factor: 12.701

9.  Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis.

Authors:  R D Zhang; I J Fidler; J E Price
Journal:  Invasion Metastasis       Date:  1991

10.  Inhibition of cyclin-dependent kinases by p21.

Authors:  J W Harper; S J Elledge; K Keyomarsi; B Dynlacht; L H Tsai; P Zhang; S Dobrowolski; C Bai; L Connell-Crowley; E Swindell
Journal:  Mol Biol Cell       Date:  1995-04       Impact factor: 4.138

View more
  1 in total

Review 1.  In vivo animal models for studying brain metastasis: value and limitations.

Authors:  Inderjit Daphu; Terje Sundstrøm; Sindre Horn; Peter C Huszthy; Simone P Niclou; Per Ø Sakariassen; Heike Immervoll; Hrvoje Miletic; Rolf Bjerkvig; Frits Thorsen
Journal:  Clin Exp Metastasis       Date:  2013-01-16       Impact factor: 5.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.